Stents: What Now?

The risk question is so important that J&J and Boston Scientific are jointly funding a massive study that might answer it.Abbott is also at a crossroads. Yesterday it announced it has abandoned Zomaxx, the drug-eluting stent it developed, after trials showed that it was less effective than Taxus and thus would suffer in the marketplace, reports Bloomberg News. It will continue development work on the Xience, the drug-eluting stent technology it acquired from Boston Scientific as part of the Guidant deal.